The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy-Reference-Cited by-同舟云学术

The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy

Published:2017-12 Issue:29 Volume:13 Page:2691-2696
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Wu Xiaohong¹,Zhou Feiqing²,Ji Xiuhai³,Ren Kewei⁴,Shan Ye⁵,Mao Xuhua⁶,Fen Yan⁷,Chen Ruhua⁷,Ding Hui⁷,Fu Xingli⁸

Affiliation:

1. Department of Gastrointestinal Surgery, Yixing People Hospital, Affiliated Jiangsu University, 214200, China

2. Department of Medical Examination Center, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China

3. Department of Oncology, Affiliated Taicang Hospital of Traditional Chinese Medicine, Suzhou, 215400, China

4. Department of Orthopedics, The Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin, 214400, China

5. Department of Critical Care Medicine, The Affiliated Yixing Hospital of Jiangsu University, Yixing, Jiangsu, 214200, China

6. Department of Clinical Laboratory, Yixing People Hospital, Affiliated Jiangsu University, 214200, China

7. Department of Respiratory Medicine, Yixing People Hospital, Affiliated Jiangsu University, 214200, China

8. Jiangsu University Health Science Center, Yizheng Road, Zhenjiang, Jiangsu, 212001, China

Abstract

Aim: We aimed to investigate a practical profile of MAC30 on chemotherapeutic response in gastric cancer (GC). Patients & methods: We elected 87 GC patients receiving platinum-based chemotherapy in this study. MAC30 levels in tumor and adjuvant nontumor tissues were confirmed via reverse transcription-PCR to identify the clinical profile in GC and the correlation with therapeutic response. Results: We found elevated MAC30 in GC compared with the matched adjacent nontumor tissues. GC with enhanced MAC30 exhibited poorer survival by Kaplan–Meier analysis and poor response to adjuvant platinum-based chemotherapy. A multivariate analysis showed that MAC30 was an independent prognostic factor of overall survival in GC receiving platinum-based chemotherapy. Conclusion: MAC30 could play as a potential biomarker for prognosis of GC with platinum-based chemotherapy.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-0426

Reference21 articles.

1. Helicobacter pylori infection, H19 and LINC00152 expression in serum and risk of gastric cancer in a Chinese population

2. Preoperative Staging and Postoperative Surveillance for Gastric Cancer

3. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction

4. MicroRNA-200c as a prognostic and sensitivity marker for platinum chemotherapy in advanced gastric cancer

5. Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of lysosomal membrane proteins in autophagy and related diseases;The FEBS Journal;2023-06-05

2. Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy;Frontiers in Oncology;2023-01-04

3. Inhibition of MAC30 exerts antitumor effects in nasopharyngeal carcinoma via affecting the Akt/GSK‐3β/β‐catenin pathway;Journal of Biochemical and Molecular Toxicology;2022-04-04

4. Transmembrane protein 97 exhibits oncogenic properties via enhancing LRP6-mediated Wnt signaling in breast cancer;Cell Death & Disease;2021-10

5. Meningioma-associated protein 30 accelerates the proliferation and invasion of hepatocellular carcinoma by modulating Wnt/GSK-3β/β-catenin signaling;Journal of Bioenergetics and Biomembranes;2021-01-06